In particular, the pre-treatment level of circulating exosomal PD-L1 are significantly higher in melanoma patients who have poor responses to anti-PD1 therapy [143], revealing that the level of circulating exosomal PD-L1 may help predict anti-PD1 response and clinical outcomes. This evidence concerns the gene CD274 and melanoma.